Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Biomed ; 92(2): e2021199, 2021 05 12.
Article in English | MEDLINE | ID: mdl-33988163

ABSTRACT

Authors present 6 cases of abdominal bleeding associated with COVID-19, representing 1.35% of all hospitalized COVID-19 patients and hypothesize that there could be, although not very frequently, a relationship between SARS-CoV2 and bleeding. They excluded a side effect of the low molecular weight heparin therapy that all patients underwent during the course of the disease or other possible causes. Alterations of the coagulation state or a weakness of the vascular wall due toa presumed endotheliitis SARS-CoV-2 infection induced, are hypothesized by the authors. Investigation and follow-up for possible hemorrhagic problems in patients with COVID-19 is recommended. In particular, clinicians should be vigilant about retroperitoneal hemorrhage in COVID-19 patients. In addition to the fact that these patients are being treated with anticoagulants, anemia and abdominal pain are the signs that should lead us to suspect this type of haemorrhage. More studies are needed to understand if COVID-19 can be directly associated with bleeding. (www.actabiomedica.it)


Subject(s)
COVID-19 , SARS-CoV-2 , Anticoagulants , Hemorrhage/chemically induced , Humans , RNA, Viral
2.
Curr Cardiol Rev ; 15(3): 219-223, 2019.
Article in English | MEDLINE | ID: mdl-30636613

ABSTRACT

In patients with atrial fibrillation undergoing percutaneous coronary intervention with the placement of stents, a triple antithrombotic therapy is empirically established, which consists of a combination of dual antithrombotic therapy (aspirin plus a P2Y12 inhibitor) and an oral anticoagulant agent. This choice is guided by the desirable result of reducing cerebrovascular and coronary ischemic events. However, there is an unwelcome outcome: an increased incidence of bleeding. On this matter, in 2018, a North American Perspective Update was published, about a year later it was followed by the publication of the European focus update on the dual antiplatelet therapy. After analysing the main differences between these two consensus documents, this review aims at examining the major studies on which they are based on, as a starting point to define the foundation of new trials that can help shed light on this prominent topic.


Subject(s)
Atrial Fibrillation/drug therapy , Drug Therapy, Combination/methods , Fibrinolytic Agents/therapeutic use , Percutaneous Coronary Intervention/methods , Platelet Aggregation Inhibitors/therapeutic use , Atrial Fibrillation/pathology , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...